Budget Impact of Treating Commercially Insured Type 1 and Type 2 Diabetes Patients in the United States with Insulin Degludec Compared to Insulin Glargine.

CONCLUSIONS: The results of this analysis suggest that the reduced insulin utilization and fewer hypoglycemic episodes associated with IDeg may translate into reduced costs for payers. The model is limited by simplification of a complex disease state and assumptions surrounding disease state, treatment patterns, and costs. Therefore, results may not accurately reflect actual health plans or real-world practice patterns.
PMID: 27764979 [PubMed - as supplied by publisher]

Source: Current Medical Research and Opinion - October 23, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research